Effect of aspirin use for primary prevention of cardiovascular diseases in type 2 diabetic patients: A retrospective cohort study
Keywords:
Primary prevention, Type 2 diabetes mellitus, Cardiovascular disease, AspirinAbstract
This retrospective cohort study aimed to investigate the association of using aspirin at a dose of 81 mg per day for primary prevention of cardiovascular events and gastrointestinal hemorrhage in patients with type 2 diabetes mellitus with the ages of 50 years or older who were at risk of ather osclerotic cardiovascular disease (ASCVD). The sample size was calculated, and obtained, 313 patients per group which were classified by aspirin group and non-aspirin group. Data were collected from medical records at Bandanlanhoi Hospital, Sukhothai Province, from July 1, 2012, to June 30, 2022, monitoring the incidence of cardiovascular disease and gastrointestinal hemorrhage for a period of 5 years. Data were analyzed by descriptive statistics composed of frequency, percentage, and Logistic regression.
The results showed that the useof aspirin was not statistically associated with cardiovascular disease (OR = 0.87, 95% CI = 0.54-1.38) and gastrointestinal hemorrhage (OR = 1.38, 95% CI = 0.68-2.80) in patients with type 2 diabetes mellitus over the age of 50 years who were at risk of atherosclerotic cardiovascular disease (ASCVD). In addition, it was found that the factors associated with cardiovascular disease including hypertension (ORadj = 2.12, 95% CI = 1.14-3.99), systolic blood pressure greater than 140 mmHg (ORadj = 1.93, 95% CI = 1.13-3.30), and diastolic blood pressure greater than 90 mmHg (ORadj = 2.47, 95% CI = 1.17-5.23). As a result, physicians should be prescribed aspirin to patients with type 2 diabetes mellitus over the age of 50 who are at risk of atherosclerotic cardiovascular disease by considering individual patient data and together with factors associated with cardiovascular disease.
References
American Diabetes Association Professional Practice Committee. (2022). Cardiovascular disease and risk management: Standards of medical care in diabetes—2022. Diabetes Care, 45(Suppl 1), S144-S174.
Capodanno, D., & Angiolillo, D. J. (2016). Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus. Circulation, 134(20), 1579-1594.
Chuemongkon, W., Boonruang, K., & Tumpoo, K. (2019). Aspirin use for the primary prevention of cardiovascular diseases in type 2 diabetic patients. Srinagarind Medical Journal, 34(2), 184-189. (in Thai)
Collins, R., Peto, R., Hennekens, C., Doll, R., Bubes, V., Buring, J. et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. The Lancet, 373(9678), 1849-1860.
Division of non communicable disease, Department of Disease Control, & Ministry of Public Health. (2022). The number of reported cases and mortality rate of 5 NCDs disease 2016-2020 by province, health service area, and country overview. Retrieved July 1, 2022, from http://www.thaincd.com/2016/mission/documents-detail.php?id=14220&tid=32&gid=1-020. (in Thai)
Khamchata, L., Dumrongpakapakorn, P., & Theeranut, A. (2018). Metabolic Syndrome: Dangerous signs required management. Srinagarind Medical Journal, 33(4), 386–395. (in Thai)
Langsted, A., & Nordestgaard, B. G. (2019). Smoking is associated with increased risk of major bleeding: A prospective cohort study. Thrombosis and Haemostasis, 119(1), 39-47.
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016). Clinical update: Cardiovascular disease in diabetes mellitus. Circulation, 133(24), 2459-2502.
Nintasen, R. (2016). Nitric oxide and atherosclerosis. Huachiew Chalermprakiet Science and Technology Journal, 2(1), 71-79. (in Thai)
Paktipat, P., Pianchana, P., Chanasopon, S., Bhongchirawattana, S., Jaikusol, R., & Pararat, P. (2020). 5 years follow-up after primary prevention of cardiovascular events with aspirin in patients with type II diabetes mellitus. Thai Journal of Pharmacy Practice, 12, 152-162. (in Thai)
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., et al. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 37(29), 2315-2381.
Rafieian-Kopaei, M., Setorki, M., Doudi, M., Baradaran, A., & Nasri, H. (2014). Atherosclerosis: Process, indicators, risk factors and new hopes. International Journal of Preventive Medicine, 5(8), 927-946.
Rosner, B. (2000). Fundamentals of Biostatistics. (5th ed.). California: Duxbury Press, Belmont.
Sirisreetreerux, S., & Bunnag, P. (2020). Aspirin for the primary prevention of cardiovascular disease in type 2 diabetes. The Journal of Chulabhorn Royal Academy, 2(3), 54-62.
Thanassoulis, G., & Aziz, H. (2022). Atherosclerosis. Retrieved July 1, 2022, from https://www.msdmanuals.com/professional/cardiovasculardisorders/arteriosclerosis/atherosclerosis.
The ASCEND Study Collaborative Group. (2018). Effects of aspirin for primary prevention in persons with diabetes mellitus. New England Journal of Medicine, 379(16), 1529-1539.
The Royal College Physicians of Thailand, DAT, Endocrine Society of Thailand, Department of medical services, & NHSO office. (2017). Clinicalpractice guideline for diabetes 2017. (3rd ed.). Pathum Thani: Romyen media Comany Limited. (in Thai)
World Health Organization. (2021). Noncommunicable diseases. Retrieved July 1, 2022, from https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Public Health Naresuan University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The published article is copyrighted by the Journal of Public Health and Health Sciences Research.
The statements that appear in each article in this academic and research journal are the personal opinions of each author and are not related to Naresuan University and other faculty members in the university. Responsibilities regarding each article are the responsibility of each author.
